文献速递脊柱关节炎

银屑病关节炎放射学关节损伤的修复:一项队列研究

Repair of radiographic joint damage in psoriatic arthritis: a cohort study.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

该队列研究对674例银屑病关节炎患者每两年进行手足放射学评估,采用改良Steinbrocker评分(mSS)定义损伤修复为关节水平mSS下降。随访7189.5人年期间,63.4%患者出现至少一个损伤关节,其中29.7%显示至少一个关节修复证据;甲氨蝶呤联合生物DMARD与关节损伤进展率降低(RR=0.48,95%CI:0.38-0.62)及修复率增加(RR=1.97,95%CI:1.13-3.45)相关。

要点

  • 银屑病关节炎中放射学损伤修复并不少见,29.7%的损伤患者至少一个关节修复。
  • 甲氨蝶呤联合生物DMARD与损伤进展率降低(RR=0.48)及修复率增加(RR=1.97)相关。
  • 研究共361个关节显示放射学改善,支持损伤修复作为可评估结局。

核心结论

  • 银屑病关节炎中与损伤修复一致的放射学改善并不罕见,甲氨蝶呤联合生物DMARD是放射学进展减慢和损伤修复的预测因素。

研究设计与样本

  • 队列研究,纳入674例银屑病关节炎患者(54.7%男性),基线平均年龄44.4岁(SD 12.8),平均病程6.3年(SD 8.0)。
  • 每两年进行手足放射学评估,采用改良Steinbrocker评分(mSS)分级,将0级和1级合并为单一状态。
  • 定义损伤修复为关节水平mSS下降,基于mSS定义状态并拟合多状态马尔可夫模型估计转移强度及预后因素影响。

主要发现

  • 总随访7189.5人年期间,428例患者(63.4%)出现至少一个损伤关节(mSS≥2)。
  • 428例损伤患者中127例(29.7%)显示至少一个关节修复证据,共361个关节显示放射学改善。
  • 在生物DMARD治疗前观察到患者损伤进展。
  • 甲氨蝶呤联合生物DMARD与关节损伤进展率降低相关(RR=0.48,95%CI:0.38-0.62)。
  • 甲氨蝶呤联合生物DMARD与损伤修复率增加相关(RR=1.97,95%CI:1.13-3.45)。

关键数值与推荐

  • 损伤修复定义为关节水平改良Steinbrocker评分(mSS)下降。
  • mSS分级中0级和1级合并为单一状态。
  • 损伤关节定义为mSS≥2。

临床怎么用

  • 在银屑病关节炎管理中,可考虑将放射学损伤修复作为评估治疗效果的结局之一。
  • 对于适合的患者,甲氨蝶呤联合生物DMARD可能有助于减缓放射学进展并促进损伤修复。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Robust evidence on the repair of radiographic damage in psoriatic arthritis (PsA) is limited. In this study, we determined the frequency of damage repair and identified its predictors. METHODS: We performed biennial radiographic assessments of the hands and feet and graded them using the modified Steinbrocker score (mSS). Grades 0 and 1 were combined as a single state. We defined damage repair as a decrease in the joint-level mSS and summarized disease characteristics using descriptive statistics. We defined states based on the mSS and fitted multistate Markov models to estimate transition intensities and assess the impact of prognostic factors on damage repair. RESULTS: We included 674 patients with PsA (54.7% male), with a mean age of 44.4 years (SD 12.8) and a mean disease duration of 6.3 years (SD 8.0) at baseline (clinic entry). Over a total follow-up of 7189.5 person-years, 428 patients (63.4%) developed at least one damaged joint (mSS ≥2) and 127 of them (29.7%) demonstrated evidence of repair in at least one joint. In total, 361 joints demonstrated radiographic improvement. Progression of damage was observed in patients prior to biologic DMARD therapy. Combination of methotrexate and biologic DMARDs was associated with a reduced progression rate for joint damage (RR = 0.48, 95% CI: 0.38-0.62) and an increased rate of damage repair (RR = 1.97, 95% CI: 1.13-3.45). CONCLUSION: Radiographic improvement consistent with damage repair is not infrequent in PsA. Concomitant treatment with biologic DMARDs and MTX is a predictor of slower radiographic progression and damage repair.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Haddad A, Kharouf F, Lee KA, et al. Repair of radiographic joint damage in psoriatic arthritis: a cohort study. Rheumatology (Oxford). 2026. PMID: 42157419. doi:10.1093/rheumatology/keag258

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。